AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (11.1 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Transcription factor-based gene therapy to treat glioblastoma through direct neuronal conversion

Xin Wang1 ( )Zifei Pei1Aasma Hossain1Yuting Bai1Gong Chen1,2 ( )
Department of Biology, Huck Institutes of Life Sciences, Pennsylvania State University, University Park, PA 16802, USA
GHM Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China
Show Author Information

Abstract

Objective

Glioblastoma (GBM) is the most prevalent and aggressive adult primary cancer in the central nervous system. Therapeutic approaches for GBM treatment are under intense investigation, including the use of emerging immunotherapies. Here, we propose an alternative approach to treat GBM through reprogramming proliferative GBM cells into non-proliferative neurons.

Methods

Retroviruses were used to target highly proliferative human GBM cells through overexpression of neural transcription factors. Immunostaining, electrophysiological recording, and bulk RNA-seq were performed to investigate the mechanisms underlying the neuronal conversion of human GBM cells. An in vivo intracranial xenograft mouse model was used to examine the neuronal conversion of human GBM cells.

Results

We report efficient neuronal conversion from human GBM cells by overexpressing single neural transcription factor Neurogenic differentiation 1 (NeuroD1), Neurogenin-2 (Neurog2), or Achaete-scute homolog 1 (Ascl1). Subtype characterization showed that the majority of Neurog2- and NeuroD1-converted neurons were glutamatergic, while Ascl1 favored GABAergic neuron generation. The GBM cell-converted neurons not only showed pan-neuronal markers but also exhibited neuron-specific electrophysiological activities. Transcriptome analyses revealed that neuronal genes were activated in glioma cells after overexpression of neural transcription factors, and different signaling pathways were activated by different neural transcription factors. Importantly, the neuronal conversion of GBM cells was accompanied by significant inhibition of GBM cell proliferation in both in vitro and in vivo models.

Conclusions

These results suggest that GBM cells can be reprogrammed into different subtypes of neurons, leading to a potential alternative approach to treat brain tumors using in vivo cell conversion technology.

Electronic Supplementary Material

Download File(s)
cbm-18-3-860-ESM.pdf (10.7 MB)

References

1

Louis D, Ohgaki H, Wiestler O, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114: 97-109.

2

Siegel R, Miller K, Jemal A. Cancer statistics, 2019 (US statistics). CA Cancer J Clin. 2019; 69: 7-34.

3

Brennan C, Verhaak R, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013; 155: 462-77.

4

McLendon R, Friedman A, Bigner D, Olson JJ, Mikkelsen T, Lehman N, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455: 1061-8.

5

Caccese M, Indraccolo S, Zagonel V, Lombardi G. PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: a concise review. Crit Rev Oncol Hematol. 2019; 135: 128-34.

6

Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Cancer Res. 2019; 38: 87.

7

Filley A, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget. 2017; 8: 91779-94.

8

Chen Y, Ma N, Pei Z, Wu Z, Do-Monte FH, Keefe S, et al. A neuroD1 AAV-based gene therapy for functional brain repair after ischemic injury through in vivo astrocyte-to-neuron conversion. Mol Ther. 2020; 28: 217-34.

9

Guo Z, Zhang L, Wu Z, Chen Y, Wang F, Chen G. In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer’s disease model. Cell Stem Cell. 2014; 14: 188-202.

10

Heinrich C, Bergami M, Gascón S, Lepier A, Viganò F, Dimou L, et al. Sox2-mediated conversion of NG2 glia into induced neurons in the injured adult cerebral cortex. Stem Cell Reports. 2014; 3: 1000-14.

11

Liu Y, Miao Q, Yuan J, Han S, Zhang P, Li S, et al. Ascl1 converts dorsal midbrain astrocytes into functional neurons in vivo. J Neurosci. 2015; 35: 9336-55.

12

Torper O, Pfisterer U, Wolf DA, Pereira M, Lau S, Jakobsson J, et al. Generation of induced neurons via direct conversion in vivo. Proc Natl Acad Sci U S A. 2013; 110: 7038-43.

13

Park N, Guilhamon P, Desai K, McAdam RE, Langille E, O’Connor M, et al. ASCL1 reorganizes chromatin to direct neuronal fate and suppress tumorigenicity of glioblastoma stem cells. Cell Stem Cell. 2017; 21: 209-24.

14

Su Z, Zang T, Liu M, Wang L, Niu W, Zhang C. Reprogramming the fate of human glioma cells to impede brain tumor development. Cell Death Dis. 2014; 5: e1463.

15

Zhao J, He H, Zhou K, Ren Y, Shi Z, Wu Z, et al. Neuronal transcription factors induce conversion of human glioma cells to neurons and inhibit tumorigenesis. PLoS One. 2012; 7: e41506.

16

Guichet P, Bieche I, Teigell M, Serguera C, Rothhut B, Rigau V, et al. Cell death and neuronal differentiation of glioblastoma stem-like cells induced by neurogenic transcription factors. Glia. 2013; 61: 225-39.

17

Cheng X, Tan Z, Huang X, Yuan Y, Qin S, Gu Y, et al. Inhibition of glioma development by ASCL1-mediated direct neuronal reprogramming. Cells. 2019; 8: 571.

18

Gao L, Huang S, Zhang H, Hua W, Xin S, Cheng L, et al. Suppression of glioblastoma by a drug cocktail reprogramming tumor cells into neuronal like cells. Sci Rep. 2019; 9: 1-14.

19

Wingett SW, Andrews S. FastQ Screen: a tool for multi-genome mapping and quality control. F1000Res. 2018; 7: 1338.

20

Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. bioinformatics. 2009; 25: 1754-60.

21

LiaoY, Smyth G, Shi W. FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014; 30: 923-30.

22

Love M, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15: 550.

23

Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016; 32: 2847-9.

24

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102: 15545-50.

25

Brulet R, Matsuda T, Zhang L, Miranda C, Giacca M, Kaspar BK, et al. NEUROD1 instructs neuronal conversion in non-reactive astrocytes. Stem Cell Reports. 2017; 8: 1506-15.

26

Chen Y, Ma N, Pei Z, Wu Z, Do-Monte F, Keefe S, et al. A NeuroD1 AAV-based gene therapy for functional brain repair after ischemic injury through in vivo astrocyte-to-neuron conversion. Molecular Therapy. 2020; 28: 217-34.

27

Ge L, Yang F, Li W, Wang T, Lin Y, Feng J, et al. In vivo Neuroregeneration to Treat Ischemic Stroke Through NeuroD1 AAV-Based Gene Therapy in Adult Non-human Primates. Front Cell Dev Biol. 2020; 8: 590008.

28

Puls B, Ding Y, Zhang F, Pan M, Lei Z, Pei Z, et al. Regeneration of Functional Neurons After Spinal Cord Injury via in situ NeuroD1-Mediated Astrocyte-to-Neuron Conversion. Front Cell Dev Biol. 2020; 8: 591883.

29

Liu M, Li W, Zheng J, Xu Y, He Q, Chen G. Differential neuronal reprogramming induced by NeuroD1 from astrocytes in grey matter versus white matter. Neural Regen Res. 2020; 15: 342-51.

30

Rivetti Di Val Cervo P, Romanov RA, Spigolon G, Masini D, Martín-Montañez E, Toledo EM, et al. Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson’s disease model. Nat Biotechnol. 2017; 35: 444-52.

31

Zhang L, Lei Z, Guo Z, Pei Z, Chen Y, Zhang F, et al. Development of neuroregenerative gene therapy to reverse glial scar tissue back to neuron-enriched tissue. Front Cell Neurosci. 2020; 14: 594170.

32

Gascón S, Murenu E, Masserdotti G, Ortega F, Russo GL, Petrik D, et al. Identification and successful negotiation of a metabolic checkpoint in direct neuronal reprogramming. Cell Stem Cell. 2016; 18: 396-409.

33

Gohlke J, Armant O, Parham FM, Smith MV, Zimmer C, Castro DS, et al. Characterization of the proneural gene regulatory network during mouse telencephalon development. BMC Biol. 2008; 6: 1-18.

34

Imayoshi I, Kageyama R. bHLH factors in self-renewal, multipotency, and fate choice of neural progenitor cells. Neuron. 2014; 82: 9-23.

35

Masserdotti G, Gillotin S, Sutor B, Drechsel D, Irmler M, Jørgensen HF, et al. Transcriptional mechanisms of proneural factors and REST in regulating neuronal reprogramming of astrocytes. Cell Stem Cell. 2015; 17: 74-88.

36

Schuurmans C, Guillemot F. Molecular mechanisms underlying cell fate specification in the developing telencephalon. Curr Opin Neurobiol. 2002; 12: 26-34.

37

Yin J, Zhang L, Ma N, Wang Y, Lee G, Hou X-Y, et al. Chemical conversion of human fetal astrocytes into neurons through modulation of multiple signaling pathways. Stem Cell Reports. 2019; 12: 488-501.

38

Zhang L, Yin J, Yeh H, Ma N-X, Lee G, Chen XA, et al. Small molecules efficiently reprogram human astroglial cells into functional neurons. Cell Stem Cell. 2015; 17: 735-47.

39

Weinstein D, Shelanski M, Liem R. Suppression by antisense mRNA demonstrates a requirement for the glial fibrillary acidic protein in the formation of stable astrocytic processes in response to neurons. J Cell Biol. 1991; 112: 1205-13.

40

Osborn M, Ludwig-Festl M, Weber K, Bignami A, Dahl D, Bayreuther K. Expression of glial and vimentin type intermediate filaments in cultures derived from human glial material. Differentiation. 1981; 19: 161-7.

41

Nedergaard M. Direct signaling from astrocytes to neurons in cultures of mammalian brain cells. Science. 1994; 263: 1768-71.

42

Madhankumar A, Mintz A, Debinski W. Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia. 2004; 6: 15-22.

43

Taylor T, Furnari F, Cavenee W. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets. 2012; 12: 197-209.

44

Westphal M, Maire C, Lamszus K. EGFR as a target for glioblastoma treatment: an unfulfilled promise. CNS Drugs. 2017; 31: 723-35.

45

Yang N, Chanda S, Marro S, Ng Y-H, Janas JA, Haag D, et al. Generation of pure GABAergic neurons by transcription factor programming. Nat Methods. 2017; 14: 621-8.

46

Zsengeller Z, Otake K, Hossain S, Berclaz P, Trapnell B. Internalization of adenovirus by alveolar macrophages initiates early proinflammatory signaling during acute respiratory tract infection. J Virol. 2000; 74: 9655-67.

47

Worgall S, Wolff G, Falck-Pedersen E, Crystal R. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther. 1997; 8: 37-44.

48

Liu Y, Chiriva-Internati M, Grizzi F, Salati E, Roman JJ, Lim S, et al. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Ther. 2001; 8: 948-57.

49

Zaiss A, Liu Q, Bowen G, Wong N, Bartlett J, Muruve D. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol. 2002; 76: 4580-90.

50

Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of adult pancreatic exocrine cells to β-cells. nature. 2008; 455: 627-32.

51

Zhao C, Teng EM, Summers RG, Ming GL, Gage FH. Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus. Journal of Neuroscience. 2006; 26: 3-11.

52

Deng L, Yao J, Fang C, Dong N, Luscher B, Chen G. Sequential postsynaptic maturation governs the temporal order of GABAergic and glutamatergic synaptogenesis in rat embryonic cultures. J Neurosci. 2007; 27: 10860-69.

Cancer Biology & Medicine
Pages 860-874
Cite this article:
Wang X, Pei Z, Hossain A, et al. Transcription factor-based gene therapy to treat glioblastoma through direct neuronal conversion. Cancer Biology & Medicine, 2021, 18(3): 860-874. https://doi.org/10.20892/j.issn.2095-3941.2020.0499

46

Views

0

Downloads

18

Crossref

18

Web of Science

17

Scopus

Altmetrics

Received: 27 August 2020
Accepted: 30 December 2020
Published: 01 August 2021
©2021 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License

Return